Drugs / BNT164b1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05537038 | Apr 2023 → Jun 2025 | tuberculosis | BioNTech SE | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05547464 | Jul 2023 → Mar 2026 overdue | tuberculosis | BioNTech SE | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT164b1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05547464 ↗ |
| Modality | Messenger RNA (mRNA) | “BNT164b1 utilizes N1-methylpseudouridine-modified mRNA” PMID 42286358 ↗ Jun 2026 |
| Route | Intramuscular | “administered as intramuscular injection” NCT05537038 ↗ |